Skip to main content

FDA Approvals

FDA Approvals, In the News
October 28, 2019 – Oncology News & Updates
Read More
Breast Cancer, FDA Approvals, In the News, Multiple Myeloma, Pediatric Cancer, Oncology
Vincristine, Racial Disparities in Multiple Myeloma, and HER2 Metastatic Breast Cancer Are in the News
Read More
FDA Approvals, Multiple Myeloma, In the News, Oncology
FDA Approves Darzalex Combination for First-Line Treatment of Transplant-Eligible Patients with Multiple Myeloma
Read More
FDA Approvals, In the News
Keytruda Approved for Patients with Previously Treated Metastatic Small-Cell Lung Cancer
Read More
FDA Approvals, In the News
First Chemoimmunotherapy Regimen Granted Accelerated Approval for Patients with Previously Treated DLBCL
Read More
FDA Approvals
Tavalisse (Fostamatinib Disodium Hexahydrate) First Spleen Tyrosine Kinase Inhibitor Approved for Chronic Immune Thrombocytopenia
Loretta Fala
Read More
Breast Cancer, FDA Approvals, In the News, Oncology
FDA Expands Indication for Kadcyla to Include the Adjuvant Treatment of HER2-Positive Early Breast Cancer
Read More
FDA Approvals, In the News
Tibsovo Now FDA Approved as First-Line Treatment for AML with IDH1 Mutation
Read More
FDA Approvals
Daurismo (Glasdegib) Approved, in Combination with Low-Dose Cytarabine, for Newly Diagnosed Acute Myeloid Leukemia in Older Adults or Those Unfit for Intensive Chemotherapy
Loretta Fala
Read More
FDA Approvals
Talzenna (Talazoparib) New PARP Inhibitor Approved for the Treatment of HER2-Negative Advanced Breast Cancer with Germline BRCA Mutation
Lisa A. Raedler, PhD, RPh
Read More
Page 13 of 21
Results 121 - 130 of 205